James E. Flynn

This profile gathers the share dealings of James E. Flynn across 19 companies, led by Larimar Therapeutics, Inc., Nuvalent, Inc. and Oncorus, Inc. We count 80 filings; the first trade dates from 20 January 2016 and the latest from 15 July 2026.

On the open market, the record shows 24 purchases worth €58.3M and 22 sales worth €139.0M. The totals exclude 18 filings filed without an amount. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. The rest of the record consists of 7 share grants and 3 option exercises. In 2026 alone, the filings show 1 purchase and no sales.

In size, the median ticket on the buying side is €9.1M. Clusters matter here: 5 out of 23 purchases overlapped with buying by a colleague within 30 days. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase.

The newest entry dates from 17 July 2026: a transaction of €899.6M, in Nuvalent, Inc. The clock since the last published purchase (2 March 2026) now reads 230 days. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. For comparison, the SEC allows two business days to file a Form 4. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.